Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 10, 2015-10 ,pp. : 565-575

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Unified Approach to Risk Assessment for Cancer and Noncancer Endpoints Based on Benchmark Doses and Uncertainty/Safety Factors1

By Gaylor D.W.   Kodell R.L.   Chen J.J.   Krewski D.  

Regulatory Toxicology and Pharmacology, Vol. 29, Iss. 2, 1999-04 ,pp. : 151-157

Academic Press

Access to resources Recommend Favorite

Comparison of Noncancer Risk Assessment Approaches for Use in Deriving Drinking Water Criteria

By Gibson M.C.   deMonsabert S.M.   Orme-Zavaleta J.  

Regulatory Toxicology and Pharmacology, Vol. 26, Iss. 3, 1997-12 ,pp. : 243-256

Academic Press

Access to resources Recommend Favorite

Cystic Fibrosis and the Use of Pharmacogenomics to Determine Surrogate Endpoints for Drug Discovery

By Eidelman O.   Zhang J.   Srivastava M.   Pollard H.B.  

American Journal of PharmacoGenomics, Vol. 1, Iss. 3, 2001-01 ,pp. : 223-238

Adis International

Access to resources Recommend Favorite

Establishing Causality of CNS Depression in Breastfed Infants Following Maternal Codeine Use

By Madadi Parvaz   Shirazi Farshad   Walter Frank G.   Koren Gideon  

Pediatric Drugs, Vol. 10, Iss. 6, 2008-01 ,pp. : 399-404

Adis International

Access to resources Recommend Favorite